Senores Pharmaceuticals is currently trading at RS. 683.85, up by 10.65 points or 1.58% from its previous closing of RS. 673.20 on the BSE.

The stock opened at RS. 687.75 and touched a high of RS. 687.75 and a low of RS. 667.65. A total of 17057 shares have been traded so far.

The BSE group 'B' stock, with a face value of RS. 10, hit a 52-week high of RS. 718.20 on July 30, 2025, and a 52-week low of RS. 440.00 on January 13, 2025. Over the last week, the stock recorded a high of RS. 687.75 and a low of RS. 632.50. The company’s current market capitalization is RS. 3154.67 crore.

The shareholding pattern shows 45.78% held by promoters, 13.18% by institutions, and 41.04% by non-institutions.

In a strategic move, Senores Pharmaceuticals, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed an agreement to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA, Inc.

The acquisition will be funded using proceeds from the company’s Initial Public Offer (IPO), in line with the objectives outlined in its Red Herring Prospectus.

Senores Pharmaceuticals is a global research-driven pharmaceutical company specializing in developing and manufacturing a wide range of generic pharmaceutical products for the B2B segment, primarily targeting regulated markets across various therapeutic areas and dosage forms.